The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety report of a phase II trial of irinotecan plus S-1 (IRIS) with cetuximab in patients with KRAS wild type of metastatic colorectal cancer: HGCSG0902.
Yoshito Komatsu
No relevant relationships to disclose
Satoshi Yuki
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Ayumu Hosokawa
No relevant relationships to disclose
Ichiro Iwanaga
No relevant relationships to disclose
Osamu Muto
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Yasushi Tsuji
No relevant relationships to disclose
Yuh Sakata
No relevant relationships to disclose